STR-324 / ArchiMed - LARVOL DELTA

Combining Leu-enkephalin nanomedicines with enkephalinase inhibitors: a promising painkiller strategy? (PubMed, Drug Deliv Transl Res) - "This study investigates the potential of a novel nanomedicine approach relying on squalene nanoparticles of endogenous enkephalinase inhibitors (EEI) - opiorphin (OPN) and STR-324 - to alleviate pain by potentiating the action of enkephalins in vivo, in a model of acute inflammatory pain. EEI-SQ NPs administered subcutaneously successfully enhanced the anti-hyperalgesic effect of LENK-SQ NPs. However, it was considered as not relevant enough regarding the observed local toxicity."

Journal • Pain • PENK

PSTR324. Alzheimer's Disease and Related Dementias: Biomarkers (Neuroscience 2025) - No abstract available

Biomarker • Alzheimer's Disease • CNS Disorders • Dementia

PSTR324. Astrocytes and Disease Mechanisms (Neuroscience 2024) - No abstract available

CNS Disorders

Influence of STR-324, a Dual Enkephalinase Inhibitor, on Postoperative Pain Scores: A Proof-of-Concept Trial in Patients after Laparoscopic Surgery. (PubMed, Anesthesiology) - No abstract available

Journal • Surgery • Pain • PENK

Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review. (PubMed, Pharmaceuticals (Basel)) - "Although traditional opioids such as morphine and oxycodone are commonly used in the management of acute postoperative pain, novel opioids may play a role as alternatives that provide potent pain relief while minimizing adverse effects...The more established include oliceridine (biased ligand activity to activate analgesia and downregulate opioid-related adverse events), tapentadol (mu-opioid agonist and norepinephrine reuptake inhibitor), and cebranopadol (mu-opioid agonist with nociceptin opioid peptide activity)-all of which have demonstrated success in the clinical setting when compared to traditional opioids. On the other hand, dinalbuphine sebacate (DNS; semi-synthetic mu partial antagonist and kappa agonist), dual enkephalinase inhibitors (STR-324, PL37, and PL265), and endomorphin-1 analog (CYT-1010) have shown good efficacy in preclinical studies with future plans for clinical trials. Rather than relying solely on mu-opioid receptor agonism to relieve pain and..."

Journal • Review • Anesthesia • CNS Disorders • Depression • Pain • Psychiatry • PENK

Enhancing Opiorphin's Metabolic Stability and Preserving its Potent Analgesic Effect: A Systematic Review. (PubMed, Curr Top Med Chem) - "This paper presents the first systematic review discussing opiorphin and opiorphin analogs and identifies the most promising candidates for future research."

Journal • Review • Pain

PSTR324. Alzheimer's Disease: Neuroinflammation and Immune Actions: In Vivo Models (Neuroscience 2023) - No abstract available

Preclinical • Alzheimer's Disease • CNS Disorders

A possible alternative to Opiorphin and its stable analogues for treating fibromyalgia pain: A clinical hypothesis. (PubMed, North Clin Istanb) - "Opiorphin is an anti-nociceptive modulator which inhibits the enzyme responsible for the degradation of natural endogenous opioid neuropeptides. This paper hypothesizes and concludes that Opiorphin and its stable analogues (Sialorphine, STR-324) can be an alternative for the treatment of chronic long-standing low-threshold tender point pain associated with fibromyalgia."

Journal • Review • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Dose Finding Study of STR-324 (clinicaltrials.gov) - P2; N=118; Recruiting; Sponsor: Alaxia SAS; Trial completion date: Jul 2021 ➔ Jan 2022; Trial primary completion date: Jul 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Pain

First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management. (PubMed, Br J Clin Pharmacol) - "STR-324 displayed favourable safety and tolerability profiles at all doses up to 11.475mg h-1. Although pharmacokinetic characterisation of STR-324 was limited, dose proportionality could be assumed based on major metabolite data assayed as proxy. No clear effects on nociceptive thresholds or other pharmacodynamic measures were observed."

Clinical • Journal • P1 data • PK/PD data • Addiction (Opioid and Alcohol) • Pain • PENK

Dose Finding Study of STR-324 (clinicaltrials.gov) - P2; N=116; Recruiting; Sponsor: Stragen France; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Pain

Dose Finding Study of STR-324 (clinicaltrials.gov) - P2; N=116; Not yet recruiting; Sponsor: Stragen France

Clinical • New P2 trial • Pain